{"nctId":"NCT00852540","briefTitle":"Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA","startDateStruct":{"date":"2009-04"},"conditions":["Skin Infections, Bacterial"],"count":410,"armGroups":[{"label":"Retapamulin","type":"EXPERIMENTAL","interventionNames":["Drug: Retpamulin Ointment, 1%"]},{"label":"Linezolid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Linezolid"]}],"interventions":[{"name":"Retpamulin Ointment, 1%","otherNames":[]},{"name":"Linezolid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 2 months of age or older\n* diagnosis of secondarily-infected traumatic lesion (SITL) or impetigo (bullous or non-bullous)\n* negative urine pregnancy test (females of childbearing potential)\n* total skin infection rating scale (SIRS) score of at least 8, which must include a pus/exudate score of at least 3\n* subject or parent/legal guardian willing and able to comply with protocol\n* written informed, dated consent, and written assent (if applicable)\n\nExclusion Criteria:\n\n* previous hypersensitivity to pleuromutilins or oxazolidinones\n* phenylketonuria or known hypersensitivity to aspartame\n* secondarily-infected animal/human bite, or puncture wound\n* abscess\n* chronic ulcerative lesion\n* underlying skin disease (eg, eczematous dermatitis) with secondary infection\n* systemic signs and symptoms of infection\n* skin infection not appropriate for treatment by a topical antibiotic (eg, extensive cellulitis, furunculosis)\n* subject requires surgical intervention for infection prior to study or likely will during the study\n* receipt of systemic antibacterial or steroid, or application of any topical therapeutic agent directly to wound within 24 hours of entry into the study\n* subject currently receiving adrenergic agents\n* subject currently receiving serotonergic agents\n* history of pseudomembranous colitis\n* known, pre-existing myelosuppression, history of myelosuppression with linezolid use, or receiving a medication that produces bone marrow suppression\n* history of siezures\n* history of severe renal failure and undergoing dialysis\n* serious underlying disease that could be imminently life-threatening\n* pregnant, breast feeding or planning a pregnancy, or not using accepted method of contraception (females of childbearing potential or \\<1 year post-menopausal)\n* use of another investigational drug within 30 days prior to entry into this study\n* previously enrolled in this study\n* fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency (for subjects \\<12 years of age receiving linezolid suspension)","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Months","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Achieving Clinical Response at Follow-up Who Had Methicillin-resistant Staphlococcus Aureus (MRSA) as a Baseline Pathogen","description":"Follow-up is defined as 7-9 days post-therapy: Day 12-14 for retapamulin; Day 17-19 for linezolid. Clinical success at follow-up was defined as the resolution of clinically meaningful signs and symptoms of infection recorded at baseline, including a pus/exudate skin infection rating scale (SIRS) score of \"0.\" The SIRS is used by the investigator to evaluate infected lesions. Scores on the SIRS range from 0 (absent) to 6 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Microbiological Response (MR) at Follow-up (FU) Who Had MRSA as a Baseline Pathogen (BP)","description":"MR was defined as microbiological success if, (1) for participants (par.) whose clinical outcome at end of therapy (EOT) was \"clinical success (CS)/improvement,\" the BP was eradicated/presumed to be eradicated at EOT, or the BP was present at EOT and absent at FU, or the BP was eradicated/presumed to be eradicated at EOT, or the BP was present at EOT and par. was a \"CS\" such that no culture was obtained due to lack of culturable material secondary to adequate clinical response; or (2) a pathogen not previously identified at baseline was isolated at FU in a par. identified at FU as a \"CS.\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Response at Follow-up","description":"Follow-up is defined as 7-9 days post-therapy: Day 12-14 for retapamulin; Day 17-19 for linezolid. Clinical success at follow-up was defined as the resolution of clinically meaningful signs and symptoms of infection recorded at baseline, including a pus/exudate skin infection rating scale (SIRS) score of \"0.\" The SIRS is used by the investigator to evaluate infected lesions. Scores on the SIRS range from 0 (absent) to 6 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved Microbiological Response (MR) at Follow-up (FU) Who Had a Baseline Pathogen (BP)","description":"MR was defined as microbiological success if, (1) for participants (par.) whose clinical outcome at end of therapy (EOT) was \"clinical success (CS)/improvement,\" the BP was eradicated/presumed to be eradicated at EOT, or the BP was present at EOT and absent at FU, or the BP was eradicated/presumed to be eradicated at EOT, or the BP was present at EOT and par. was a \"CS\" such that no culture was obtained due to lack of culturable material secondary to adequate clinical response; or (2) a pathogen not previously identified at baseline was isolated at FU in a par. identified at FU as a \"CS.\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Clinical Outcome at the End of Therapy Who Had MRSA as a Baseline Pathogen","description":"Clinical improvement is defined as improvement of signs/symptoms of infection recorded at baseline (BL) to such an extent that no further antimicrobial therapy is necessary. Clinical failure (CF) is defined as insufficient improvement/deterioration of signs/symptoms of the infection recorded at BL, such that additional antibiotic therapy is required. Unable to determine (UTD) is defined as refusal to consent to a clinical examination, lost to follow-up. Participants who are \"CF\"/\"Unable to Determine\" at end of therapy are considered such at follow-up as well.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Microbiological Outcome at the End of Therapy Who Had MRSA as a Baseline (BL) Pathogen","description":"Eradication is the elimination of BL pathogens. Presumed eradication and presumed improvement are clinical outcomes of success or improvement, respectively, such that no culture was obtained due to lack of culturable material, secondary to adequate clinical response, and is documented in the electronic Case Report Form. Persistence is defined as BL pathogens still being present. Presumed persistence is defined as a participant that is a clinical failure with no obtained culture. \"Unable to determine\" was used if no determination of BL pathogen microbiological response could be made.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Clinical Outcome at the End of Therapy","description":"Clinical improvement is defined as improvement of signs/symptoms of infection recorded at baseline (BL) to such an extent that no further antimicrobial therapy is necessary. Clinical failure (CF) is defined as insufficient improvement/deterioration of signs/symptoms of the infection recorded at BL, such that additional antibiotic therapy is required. Unable to determine (UTD) is defined as refusal to consent to a clinical examination, lost to follow-up. Participants who are \"CF\"/\"Unable to Determine\" at end of therapy are considered such at follow-up as well.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Baseline Pathogens With the Indicated Microbiological Outcome at the End of Therapy","description":"Eradication is the elimination of BL pathogens. Presumed eradication and presumed improvement are clinical outcomes of success or improvement, respectively, such that no culture was obtained due to lack of culturable material, secondary to adequate clinical response, and is documented in the electronic Case Report Form. Persistence is defined as BL pathogens still being present. Presumed persistence is defined as a participant that is a clinical failure with no obtained culture. \"Unable to determine\" was used if no determination of BL pathogen microbiological response could be made.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Therapeutic Response at Follow-up","description":"Therapeutic response is defined as the combined clinical and microbiological response. Therapeutic response iss a measure of the overall efficacy response, and a therapeutic success refers to participants who had been deemed both a \"clinical success\" and a \"microbiological success.\" All other combinations (other than \"clinical success\" + \"microbiological success\") were deemed failures for therapeutic response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Scores on the Skin Infection Rating Scale at Visits 1, 2, 3, 4, and 5","description":"The investigator evaluated skin infections by grading the infected lesion for exudate (a fluid that leaks out of blood vessels into surrounding tissue)/pus, crusting, erythema (redness of the skin)/ inflammation (E/I), tissue warmth, tissue edema (swelling), itching, and pain, according to the Skin Infection Rating Scale. All parameters were graded on a scale of 0 (absent) to 6 (severe). The total score is calculated by summing the individual scores from the 7 parameters; the total score ranges from 0 to 42.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"0.82"},{"groupId":"OG001","value":"3.6","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.37"},{"groupId":"OG001","value":"1.4","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.05"},{"groupId":"OG001","value":"0.4","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.59"},{"groupId":"OG001","value":"0.1","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.39"},{"groupId":"OG001","value":"0.0","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.48"},{"groupId":"OG001","value":"2.1","spread":"1.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.21"},{"groupId":"OG001","value":"1.2","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.08"},{"groupId":"OG001","value":"0.8","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.95"},{"groupId":"OG001","value":"0.5","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.59"},{"groupId":"OG001","value":"0.3","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.09"},{"groupId":"OG001","value":"3.4","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.19"},{"groupId":"OG001","value":"2.2","spread":"1.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.15"},{"groupId":"OG001","value":"1.0","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.69"},{"groupId":"OG001","value":"0.5","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.54"},{"groupId":"OG001","value":"0.2","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.33"},{"groupId":"OG001","value":"2.6","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.22"},{"groupId":"OG001","value":"1.3","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.97"},{"groupId":"OG001","value":"0.4","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.41"},{"groupId":"OG001","value":"0.1","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.38"},{"groupId":"OG001","value":"0.0","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.24"},{"groupId":"OG001","value":"2.7","spread":"1.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.23"},{"groupId":"OG001","value":"1.5","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.02"},{"groupId":"OG001","value":"0.7","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.60"},{"groupId":"OG001","value":"0.2","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.35"},{"groupId":"OG001","value":"0.1","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.51"},{"groupId":"OG001","value":"1.8","spread":"1.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.27"},{"groupId":"OG001","value":"0.9","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.24"},{"groupId":"OG001","value":"0.6","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.79"},{"groupId":"OG001","value":"0.4","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.42"},{"groupId":"OG001","value":"0.2","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.57"},{"groupId":"OG001","value":"3.0","spread":"1.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.56"},{"groupId":"OG001","value":"1.2","spread":"1.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.14"},{"groupId":"OG001","value":"0.4","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.60"},{"groupId":"OG001","value":"0.1","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.39"},{"groupId":"OG001","value":"0.1","spread":"0.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"5.69"},{"groupId":"OG001","value":"19.2","spread":"5.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"6.78"},{"groupId":"OG001","value":"9.7","spread":"6.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"5.83"},{"groupId":"OG001","value":"4.1","spread":"4.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"6.13"},{"groupId":"OG001","value":"2.5","spread":"4.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"6.14"},{"groupId":"OG001","value":"1.6","spread":"3.92"}]}]}]},{"type":"SECONDARY","title":"Mean Wound Size at Visits 1, 2, 3, 4, and 5","description":"Lesion sized was measured in centimeters squared at Visits 1, 2, 3, 4, and 5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.942","spread":"13.3124"},{"groupId":"OG001","value":"5.620","spread":"9.6215"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.963","spread":"8.5492"},{"groupId":"OG001","value":"4.115","spread":"9.4305"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.270","spread":"10.8663"},{"groupId":"OG001","value":"1.776","spread":"6.7537"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.556","spread":"5.2201"},{"groupId":"OG001","value":"0.812","spread":"3.4217"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.741","spread":"3.5977"},{"groupId":"OG001","value":"0.588","spread":"3.3623"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":267},"commonTop":["Diarrhea","Nausea"]}}}